| 52-Week High | 37.99 |
|---|---|
| Last Price | 37.36 |
| Fibonacci 61.8% | 28.02 |
| Fibonacci 50% | 24.95 |
| Fibonacci 38.2% | 21.87 |
What are analysts'target prices for Translate Bio's stock?
8 brokerages have issued 1 year target prices for Translate Bio's stock. Their forecasts range from $20.00 to $38.00. On average, they anticipate Translate Bio's share price to reach $27.50 in the next twelve months. This suggests that the stock has a possible downside of 26.4%.
What is the upside for Translate Bio's stock?
On average, they expect Translate Bio's stock price to reach $21.60 in the next twelve months. This suggests a possible upside of 145.5% from the stock's current price. View Analyst Price Targets for Translate Bio.
Why did Translate Bio's share price surge 30%?
Shares of Translate Bio surged 30% on Tuesday after Sanofi agreed to buy the mRNA developer for $3.2 billion. Sanofi will purchase Translate Bio for $38 per share in cash and fast track its mRNA technology. The move comes following the success of Moderna, which developed a mRNA-based COVID-19 vaccine.
Are Translate Bio insiders buying or selling stock?
In the past three months, Translate Bio insiders have not sold or bought any company stock. Only 9.40% of the stock of Translate Bio is held by insiders. 88.84% of the stock of Translate Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Is translate bio a good stock to buy?
The consensus among Wall Street equities research analysts is that investors should "hold" Translate Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBIO, but not buy additional shares or sell existing shares.
Why is translate bio stock down?
Translate Bio stock slid steeply Thursday in response to disappointing trial data. The messenger RNA-focused biotech Translate Bio unveiled long-awaited trial data on an experimental cystic fibrosis therapy late Wednesday. And while the data showed that the treatment was generally safe, it also doesn't seem to work.
What happened to translate bio stock?
As of September 14, 2021, Translate Bio common stock will cease to be traded on the NASDAQ Global Select Stock Market. Morgan Stanley & Co. International plc acted as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP acted as legal counsel.
Who bought Tbio stock?
What happened. Shares of Translate Bio (TBIO) surged 29% on Tuesday after the U.S. biotechnology company said it agreed to be acquired by French pharmaceutical giant Sanofi (SNY -0.26%).
Why is translate bio stock up?
Translate Bio stock was soaring on reports of a Sanofi takeover bid. Translate Bio stock is soaring after Sanofi agreed to acquire the company specializing in messenger RNA technology, the same used by Moderna and BioNTech in their Covid-19 vaccines.
Who bought Sanofi?
BayerIn October 2001, Bayer and Aventis announced that Bayer would acquire the unit for about $6.6 billion, with the unit becoming Bayer CropScience and making Bayer the world's second-largest agrochemical company behind Syngenta.
What is Tbio?
Definition. TBIO. Turn Beauty Inside Out. Copyright 1988-2018 AcronymFinder.com, All rights reserved.
How many employees does translate Bio have?
Translate Bio has 81 employees.
How do you translate in Instagram bio?
Captions and comments on posts in feed, as well as the bio you include on your profile, are translated automatically based on the language they're written in and the language settings of the person viewing it. If your language is available as a translation, you can tap See Translation below the text to see it.
Should I buy or sell Translate Bio stock right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 hold rating...
What is Translate Bio's stock price forecast for 2022?
4 brokers have issued 12-month price targets for Translate Bio's stock. Their TBIO stock forecasts range from $38.00 to $38.00. On average, they an...
How were Translate Bio's earnings last quarter?
Translate Bio, Inc. (NASDAQ:TBIO) issued its quarterly earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share (E...
Who are Translate Bio's key executives?
Translate Bio's management team includes the following people: Ilan Danieli , Chief Executive Officer & Director Ahmed Zaki Sabet , Chief Operat...
What is Craig J. Tuttle's approval rating as Translate Bio's CEO?
13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com . Craig J. Tuttle has an approval rating of 5% among Translate Bio's em...
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Qiagen (QGEN) , Qiagen (QGEN) , Neurocrine Biosciences (NBIX) , Repligen (RGEN) , Hal...
What other stocks do shareholders of Translate Bio own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals...
When did Translate Bio IPO?
(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.0...
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
Investors are disappointed with the company's latest clinical update
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Translate Bio ( NASDAQ:TBIO) were tanking 31.8% as of 11:26 a.m. EDT on Thursday. The big drop came after the company announced results following the market close on Wednesday from a second interim data analysis of a phase 1/2 study of MRT5005 in treating cystic fibrosis (CF).
So what
The big story from Translate Bio's latest results was that no clear improvement was observed in lung function among patients receiving MRT5005. SVB Leerink analyst Geoffrey Porges summed it up in a note to investors by stating, "the trial failed."
Now what
Translate Bio plans to continue studying MRT5005 in treating CF. However, the main potential catalysts for the biotech stock could come from its other pipeline programs. Translate Bio and its partner Sanofi recently began a phase 1/2 study of their messenger RNA COVID-19 vaccine candidate.
